TSBX - Turnstone Biologics Corp.


0.3703
-0.009   -2.349%

Share volume: 44,501
Last Updated: 04-07-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.02%

PREVIOUS CLOSE
CHG
CHG%

$0.38
-0.01
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
24%
Profitability 25%
Dept financing 6%
Liquidity 75%
Performance 15%
Company vs Stock growth
vs
Performance
5 Days
-1.78%
1 Month
2.95%
3 Months
-27.53%
6 Months
-19.67%
1 Year
-87.98%
2 Year
-96.63%
Key data
Stock price
$0.37
P/E Ratio 
0.00
DAY RANGE
$0.33 - $0.38
EPS 
-$0.92
52 WEEK RANGE
$0.33 - $3.88
52 WEEK CHANGE
-$89.48
MARKET CAP 
12.885 M
YIELD 
N/A
SHARES OUTSTANDING 
23.128 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
-0.22
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$163,310
AVERAGE 30 VOLUME 
$132,128
Company detail
CEO: Sammy Farah
Region: US
Website: turnstonebio.com
Employees: 0
IPO year: 2023
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

We are a clinical stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. Turnstone Biologics Inc. was incorporated as a Canadian corporation on March 27, 2014. On December 13, 2018, we incorporated Turnstone Biologics Corp., a corporation under the laws of the State of Delaware. On December 14, 2018, we completed a reorganization from Canada to the United States, which we refer to as the Reorganization. In connection with the Reorganization, all of the shareholders of Turnstone Canada exchanged their shares in Turnstone Canada for shares of our new incorporated Delaware entity, as a result of which Turnstone Canada became our wholly owned subsidiary. Our principal executive offices are located at 9310 Athena Circle, Suite 300, La Jolla, California.

Recent news
loading